| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.40▼ | 3.55▼ | 3.56▼ | 3.61▼ | 3.65▼ |
| MA10 | 3.41▼ | 3.70▼ | 3.75▼ | 3.63▼ | 3.84▼ |
| MA20 | 3.61▼ | 3.60▼ | 3.59▼ | 3.72▼ | N/A |
| MA50 | 3.54▼ | 3.78▼ | 3.95▼ | N/A | N/A |
| MA100 | 3.96▼ | 4.07▼ | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.026▼ | -0.018▼ | -0.007▼ | -0.041▼ | N/A |
| RSI | 41.781▼ | 43.044▼ | 41.837▼ | 43.224▼ | N/A |
| STOCH | 8.841▼ | 11.927▼ | 25.522 | 50.287 | N/A |
| WILL %R | -100.000▼ | -100.000▼ | -91.919▼ | -85.345▼ | N/A |
| CCI | -96.923 | -125.107▼ | -96.507 | -37.167 | N/A |
|
Wednesday, June 25, 2025 04:45 AM
The on-going Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical ...
|
|
Friday, June 06, 2025 04:45 AM
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ... (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
|
|
Tuesday, April 15, 2025 02:33 PM
Explore Intercont (Cayman) stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for NCT.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 30/06/25 | 3.71 | 4.01 | 3.30 | 3.30 | 29,289 |
| 27/06/25 | 3.60 | 3.90 | 3.54 | 3.62 | 10,300 |
| 26/06/25 | 3.54 | 3.89 | 3.54 | 3.54 | 7,200 |
| 25/06/25 | 3.75 | 3.95 | 3.56 | 3.95 | 11,300 |
| 24/06/25 | 4.19 | 4.29 | 3.60 | 3.63 | 29,900 |
| 23/06/25 | 4.10 | 4.25 | 3.975 | 4.21 | 43,400 |
| 20/06/25 | 3.46 | 3.98 | 3.37 | 3.95 | 28,300 |
| 18/06/25 | 3.25 | 3.47 | 3.14 | 3.25 | 5,700 |
| 17/06/25 | 3.34 | 3.57 | 3.15 | 3.15 | 54,200 |
| 16/06/25 | 3.50 | 3.66 | 3.13 | 3.66 | 38,717 |
|
|
||||
|
|
||||
|
|